Currently Viewing:
American Society of Hematology
Julie Wolfson: Supporting AYAs Before and After Treatment
January 14, 2018
Dr Julie Wolfson on What Clinicians Need to Understand About Adolescents/Young Adults With ALL
December 30, 2017
Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma
December 29, 2017
Dr Stephen Schuster on Institution Commitments to Deliver CAR T Therapies
December 28, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017
Currently Reading
Diagnosing Congenital Neutropenia
December 23, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16, 2017
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 12, 2017
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 12, 2017
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12, 2017
Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures
December 12, 2017
CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients
December 11, 2017
Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care
December 11, 2017
Dr Nina Shah on the Benefits of Outpatient HSCT When Possible
December 11, 2017
Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH
December 11, 2017
CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma
December 11, 2017
Balancing Hospice Utilization With the Need for Transfusion in Leukemia
December 11, 2017

Diagnosing Congenital Neutropenia

Laura Joszt
Physicians caring for patients with severe congenital neutropenia should be ready to detect issues with multiple systems in the body, explained Seth Corey, MD, of the Virginia Commonwealth University and the Massey Cancer Center & Children's Hospital of Richmond, during a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia.
Most cases of neutropenia are acquired due to treatment, but there are also congenital neutropenias, which encompass a family of neutropenic disorders.

Physicians caring for patients with severe congenital neutropenia should be ready to detect issues with multiple systems in the body, explained Seth Corey, MD, of the Virginia Commonwealth University and the Massey Cancer Center & Children's Hospital of Richmond, during a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia.

He provided the example of how the pancreas is involved in Shwachman–Diamond syndrome, in which the bone marrow malfunctions and some or all types of white blood cells are not created.

“When you have a patient with severe chronic neutropenia, one should look at the eyes, heart, skin, bone, the nervous system…” Corey said.

Individuals with severe congenital neutropenia have a shortage of neutrophils and are prone to recurrent infections. According to Corey, as much as 30% of severe congenital neutropenia is unclassified.

Corey also provided a new workup approach. The current approach begins with a history of onset of neutropenia, documentation, review of past and present infections, family history, and diet. There should also be a physical examination of sites of infection and an exam of skeletal anomalies. A second tier of evaluation includes a bone marrow aspiration and biopsy and blood counts twice a week. Then individuals will typically send off for gene sequencing.

However, Corey introduced a potential third-tier workup. When considering the cost of multiple visits and blood counts, just sending off for gene sequencing may be more cost effective. The third tier is robust next-generation sequencing (NGS) panels to get an idea of the number of different conditions. The cost of NGS panels can be about $2000 at a flat rate, but can be as much as $4000 with a turnover time of 4 to 6 weeks.

“But next generation sequencing is not going to solve everything,” Corey said.

A Canadian study looked at a panel of 72 genes in individuals with known inherited bone marrow failure syndrome, and they were only able to come up with the genetic cause in about 60%. In patients with suspected inherited bone marrow failure syndrome, the success rate was only about 20%, he said.

Corey concluded by summarizing that congenital neutropenias are a “perplexing group of conditions” and that physicians have to go through a thought process to diagnose and treat them.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!